RCUS Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
41.0M
+141.2%
17.0M
-48.5%
33.0M
+26.9%
26.0M
-83.8%
160.0M
Cost of Revenue
0
0
0
0
0
Gross Profit
41.0M
+141.2%
17.0M
-48.5%
33.0M
+26.9%
26.0M
-83.8%
160.0M
Operating Expenses
137.0M
-9.3%
151.0M
+2.7%
147.0M
-12.5%
168.0M
+0.0%
168.0M
R&D
113.0M
-7.4%
122.0M
+0.8%
121.0M
-14.2%
141.0M
+1.4%
139.0M
SG&A
24.0M
-17.2%
29.0M
+11.5%
26.0M
-3.7%
27.0M
-6.9%
29.0M
Operating Income
-96000000
+28.4%
-134000000
-17.5%
-114000000
+19.7%
-142000000
-1675.0%
-8000000
EBITDA
-93000000
+29.5%
-132000000
-18.9%
-111000000
+20.7%
-140000000
-2233.3%
-6000000
Net Income
-91000000
+28.9%
-128000000
-20.8%
-106000000
+21.5%
-135000000
0
EPS (Basic)
$-0.72
+29.4%
$-1.02
-14.6%
$-0.89
+29.9%
$-1.27
$0.00
EPS (Diluted)
$-0.72
+29.4%
$-1.02
-13.3%
$-0.90
+29.1%
$-1.27
$0.00
Shares (Diluted)
126.1M
+0.6%
125.4M
+6.1%
118.2M
+11.0%
106.5M
+0.0%
106.5M
Arcus Biosciences (RCUS) โ€” Financials